(All fields required)
Please enter a valid email.
Please enter your name.
The Brain and Spinal Tumors Program is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Maryam Fouladi, MD, MSc, FRCPC Medical Director, Neuro-Oncology Program 513-636-4266 firstname.lastname@example.org
Medical Director, Neuro-Oncology Program
Chair, Pediatric Brain Tumor Consortium Steering Committee
Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network
Professor, UC Department of Pediatrics
Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a neuro-oncology faculty member in 2000. She served as the chair of the Phase I Committee at St. Jude.
Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the steering committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Human Biology, University of Toronto, Toronto, Canada, 1987. MD: University of Toronto, Toronto, Canada, 1991.MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53.Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. Mar 15;112(6):1345-53. Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer. 2007 Dec 1;110(11):2535-41. Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol. 2007 Oct 20;25(30):4806-12. Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol. 2007 Apr 20;25(12):1532-8.Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer. 2006 107:2291-2297.
Fouladi M. Histone deacetylase inhibitors. Cancer Invest. 2006 (5):521-7.
Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol . 2006 3:287-99.
Qing Richard Lu, PhD Scientific Director, Brain Tumor Center 513-636-7684 email@example.com
Scientific Director, Brain Tumor Center
BS: Peking Normal University, Beijing, China, 1988.
MS: Rutgers University, Piscataway, NJ, 1993.
PhD: Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, 1997.
Postdoctoral Fellow: Dana Farber Cancer Institute, Harvard Medical School, Cambridge, MA, 1997 - 2002.
Deng Y, Kim B, He X, Kim S, Lu C, Wang H, Cho SG, Hou Y, Li J, Zhao X, Lu QR. Direct visualization of membrane architecture of myelinating cells in transgenic mice expressing membrane-anchored EGFP. Genesis. 2014;52:341-349.
Dai Z M, Sun S, Wang C, Huang H, Hu X, Zhang Z, Lu QR, Qiu M. Stage-Specific Regulation of Oligodendrocyte Development by Wnt/beta-Catenin Signaling. J Neurosci. 2014;34:8467-8473.
Shen YA*, Chen Y*, Dao DQ, Mayoral SR, Wu L, Meijer D, Ullian EM, Chan JR#, Lu QR# Phosphorylation of LKB1/Par-4 Establishes Schwann Cell Polarity to Initiate and Control Myelin Extent. Nature Communications. 2014 Sep 26;5:4991. # Co-corresponding author.
He X, Zhang L, Chen Y, Remke M, Shih D, Lu F, Wang H, Deng Y, Yu Y, Xia Y, Wu X, Ramaswamy V, Hu T, Wang F, Zhou W, Burns DK, Kim SH, Kool M, Pfister S, Weinstein LS, Pomeroy S, Gilbertson R, Rubin JB, Hou Y, Wechsler-Reya R, Taylor MD, Lu QR. The G-protein Alpha Subunit Gsα Is A Tumor Suppressor In Sonic Hedgehog driven Medulloblastoma. Nature Medicine. 2014 Sep;20(9):1035-42.
Hennen S*, Wang H*, Peters L, Merten N, Simon K, Spinrath A, Blättermann S, Akkari R, Schrage R, Schröder R, Schulz D, Vermeiren C, Zimmermann K, Kehraus S, Drewke C, Pfeifer A, König G, Mohr K, Gillard M, Müller C, Lu QR, Gomeza J, Kostenis E. Decoding signaling and function of the orphan G protein-coupled receptor Gpr17 with a small molecule agonist. Sci Signal. 2013 Oct 22;6(298):ra93. *Co-first authors.
Limpert AS, Bai S, Narayan M, Wu J, Yoon SO, Carter BD*, Lu QR*. NF-kB forms a complex with the chromatin remodeler BRG1 to regulate Schwann cell differentiation. J Neurosci. 2013 Feb 6;33(6):2388-97. *Co-corresponding authors.
Yu Y, Chen Y, Kim B, Wang H, Zhao C, He X, Liu L, Liu W, Wu, LM, Mao M, Chan JR, Wu J, Lu QR. Olig2 targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation. Cell. 2013 Jan 17;152(1-2): 248–261.
Chong SY, Rosenberg SS, Fancy SP, Zhao C, Shen YA, Hahn AT, McGee AW, Xu X, Zheng B, Zhang LI, Rowitch DH, Franklin RJ, Lu QR*, Chan JR*. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci U S A. 2012 Jan 24:109(4):1299-304. * Co-corresponding authors.
Weng Q, Chen Y, Wang H, Xu X, Yang B, He Q, Shou W, Higashi Y, van den Berghe V, Seuntjens E, Kernie SG, Bukshpun P, Sherr EH, Huylebroeck D, Lu QR. Dual-mode modulation of Smad signaling by Smad-interacting protein Sip1 is required for myelination in the central nervous system. Neuron. 2012 Feb 23;73(4):713-28.
Chen Y, Wang H, Yoon SO, Xu X, Hottiger MO, Svaren J, Nave KA, Kim HA, Olson EN, Lu QR. HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination. Nat Neurosci. 2011 April;14(4):437-41.
Zhao XH, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QS, Xin M, Wang F, Appel B, Lu QR. MicroRNA-Mediated Control of Oligodendrocyte Differentiation. Neuron. 2010 Mar 11; 65(5):612-26.
Chen Y, Wu H, Wang S, Koito H, Li J, Ye F, Hoang J, Escobar SS, Arnett HA, Trapp BD, Karandikar NJ, Hsieh J, Lu QR. The oligodendrocyte-specific G-protein coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat Neurosci. 2009 Nov;12(11):1398-406.
Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, Bu H, Taketo MM, van Es JH, Clevers H, Hsieh J, Bassel-Duby R, Olson EN, Lu QR. Histone Deacetylases 1 and 2 Regulate Oligodendrocyte Differentiation By Disrupting beta-Catenin TCF Interaction. Nat Neurosci. 2009 Jul;12(7):829-38.
A Novel Model of Medulloblastoma to Define Cancer Pathways and Molecular Targets. Principal Investigator. National Institutes of Health (NINDS). April 2012 – March 2017. 1R01NS078092.
Molecular Mechanisms of Oligodendrocyte Differentiation and Myelination. Principal Investigator. National Institutes of Health (NINDS). Sept 2010 – Aug 2015. 1R01NS072427.
Chromatin Remodeling Control of CNS Myelination and Remyelination. Principal Investigator. National Institutes of Health (NINDS). April 2012 – March 2017. 1R01NS075243-01.
MicroRNA control of Myelination and Remyelination in the Central Nervous System. Principal Investigator. National Multiple Sclerosis Society. July 2012 – June 2015. RG-4727-A-6-0-1.
Lionel M. L. Chow, MD, PhD Member, Cancer Biology and Neural Tumors Program 513-803-1369 firstname.lastname@example.org
Member, Cancer Biology and Neural Tumors Program
St. Baldrick’s Foundation Scholar
Sontag Foundation Distinguished Scientist
Assistant Professor, UC Department of Pediatrics
Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk.
Following his clinical training in pediatrics and pediatric hematology / oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tenn., to pursue his research interests.
Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.
Hummel, TR, Chow, LML, Fouladi, M, and Franz, D. Pharmacotherapeutic management of pediatric astrocytomas: current and upcoming strategies. Pediatric Drugs 2013; 15:29-42.
Joshi, K, Banasavadi-Siddegowda, Y, Mo, X, Kim, SH, Mao, P, Kig, C, Nardini, D, Sobol, RW, Chow, LML, Kornblum, HI, Waclaw, R, Beullens, M, and Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013; 31:1051-1063.
Zhong, Y, Wan, Y-W, Pang, K, Chow, LML, and Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013; 14:89.
Rafalski, VA, Ho, PP, Brett, JO, Ucar, D, Dugas, JC, Pollina, EA, Chow, LML, Ibrahim, A, Baker, SJ, Barres, BA, Steinman, L, and Brunet, A. Expansion of oligodendrocyte progenitor cells upon SIRT1 inactivation in the adult brain. Nature Cell Biol. 2013; 15:614-624.
Wojton, J, Chu, Z, Mathsyaraja, H, Meisen, WH, Denton, N, Kwon, C-H, Chow, LML, Palascak, M, Franco, R, Bourdeau, T, Thornton, S, Ostrowski, MC, Kaur, B, and Qi, X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013; 21:1517-1525.
Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316. Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460.
Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5. Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28.
2013 – 2014 Sophie’s Angel Run Foundation“Preclinical Testing of Notch and mTor Inhibition in a Mouse Model for High-Grade Glioma”
2011 – 2014 St. Baldrick’s Foundation Scholars Award"Molecular targeting of pediatric high-grade glioma"
2011 – 2015 Sontag Foundation Distinguished Scientist Award"Molecular targeting of high-grade astrocytoma"
Trent R. Hummel, MD 513-803-1126 email@example.com
Neuro-oncology; CNS tumors in neurofibromatosis type 1 and 2 research interests: developing novel therapeutics in central nervous system tumors including those with very poor prognosis such as high grade gliomas and diffuse intrinsic pontine gliomas.
Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of assistant professor of pediatrics.
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Hummel TR, Chow LM, Fouladi M, Franz D. Pharmacotherapeutic Management of Pediatric Gliomas: Current and Upcoming Strategies. Pediatric Drugs. 2012.
Hummel TR, Miles L, Mangano FT, Jones BV, Geller JI. Clinical heterogeneity of desmoplastic infantile ganglioglioma: a case series and literature review. J Pediatr Hematol Oncol. 2012 Aug;34(6):e232-6.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu G. Visual outcomes in children with neurofibromatosis type 1–associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun;14(6):790-7.
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7.
Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-Related Plexiform Neurofibroma to High Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.
Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner V, Wallace M, Lázaro C, Page G, Worley P, Aronow B, Schorry E, Ratner N. Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin. Clin Cancer Res. 2010 Oct 15;16(20):5048-57.
Hummel T, Hord J. Favorable Response to Soft Tissue Sarcoma Therapy in Adolescent with Embryonal Renal Sarcoma. Pediatr Blood Cancer. 2004 Jul; 43(1):70-2.
John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs 513-636-8241 firstname.lastname@example.org
Director, Division of Oncology and Cancer Programs
Deb Kleisinger Endowed Chair of Novel Cancer Treatments
Executive Co-Director, Cancer and Blood Diseases Institute
Director, Leukemia / Lymphoma Program
Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)
Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium
Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials
Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development
John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.
Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.
Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.
Mary Sutton, MD 513-636-4222
MD: University of Rochester School of Medicine and Dentistry, Rochester, NY, 1989.
Residency: Pediatrics, Children's Hospital, Boston, MA.
Fellowship: Neurology, Children's Hospital, Boston, MA.
Certification: Pediatrics, 1996; Neurology, 1996.
William S. Ball, MD Neuroradiologist, Department of Radiology and Medical Imaging 513-636-8574 email@example.com
Neuroradiologist, Department of Radiology and Medical Imaging
Research Consultant, Department of Radiology and Medical Imaging
Professor, UC Department of Radiology
UC Department of Pediatrics, UC Department of Biomedical Engineering
William Ball, MD, received his undergraduate degree in biochemistry from Louisiana State University. He is a graduate of Tulane Medical School, and is board certified in both pediatrics and radiology with added certification in Neuroradiology. He joined the faculty in Radiology at Cincinnati Children's in 1984, and became chief of section in Pediatric Neuroradiology, a position he held from 1988-2001.
In 1991, Dr. Ball developed and created the Imaging Research Center (IRC) at Cincinnati Children's, and served as its director from April 1991-2002. As a researcher, Dr. Ball has contributed over 123 scientific contributions to literature, 11 book chapters and was the editor of a complete text Pediatric Neuroradiology that is still in circulation today. He is currently a tenured professor in biomedical engineering, radiology and pediatrics.
Dr. Ball became chair of the newly formed Department of Biomedical Engineering (UCBME) at UC in 2001, a position he held until 2008. In 2008, Dr. Ball returned to Cincinnati Children’s Hospital as full-time attending staff neuroradiologist where he continued his research in pediatric cerebrovascular occlusive disease with a focus on Sickle Cell Disease (SCD). He returned to the university in August of 2011 as interim vice-president for research. He retired from the practice of neuroradiology in December of 2012 to become permanent vice-president for research at the University of Cincinnati. He continues his research in pediatric CVD at Cincinnati Children’s Hospital under a multi-institutional grant from NIH in SCD.
Blaise V. Jones, MD Chief, Neuroradiology 513-636-8574 firstname.lastname@example.org
Associate Director for Clinical Operations
Medical Director, MRI
Pediatric neuroradiology; cerebrovascular disease; neuro-oncology
Blaise V. Jones, MD, completed his undergraduate work at Duke University in 1984 and received his MD from Georgetown University in 1988. Dr. Jones did his radiology residency and neuroradiology fellowship at the University of Cincinnati and a pediatric neuroradiology fellowship at Cincinnati Children's Hospital Medical Center.
Dr. Jones was an assistant professor of radiology and pediatrics and section chief of MR imaging at the M.S. Hershey Center of the Penn State University School of Medicine before joining the pediatric neuroradiology faculty at Cincinnati Children's.
He is past president of the American Society for Pediatric Neuroradiology and former chair of the Pediatric Neuroradiology Committee of the Society for Pediatric Radiology. He is an examiner for the American Board of Radiology in Neuroradiology.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2010 Oct 16.
Donnelly LF, Gessner KE, Dickerson JM, Koch BL, Towbin AJ, Lehkamp TW, Moskovitz J, Brody AS, Dumoulin CL, Jones BV. Quality initiatives: department scorecard: a tool to help drive imaging care delivery performance. Radiographics. 2010 Nov;30(7):2029-38.
Air EL, Yuan W, Holland SK, Jones BV, Bierbrauer K, Altaye M, Mangano FT. Longitudinal comparison of pre- and postoperative diffusion tensor imaging parameters in young children with hydrocephalus. J Neurosurg Pediatr. 2010 Apr;5(4):385-91.
Morales H, Jones BV, Leach JL, Abruzzo TA. Documented development of a dural arteriovenous fistula in an infant subsequent to sinus thrombosis: case report and review of the literature. Neuroradiology. 2010 Mar;52(3):225-9. Review.
Yuan W, Mangano FT, Air EL, Holland SK, Jones BV, Altaye M, Bierbrauer K. Anisotropic diffusion properties in infants with hydrocephalus: a diffusion tensor imaging study. AJNR Am J Neuroradiol. 2009 Oct;30(9):1792-8.
Stevens J, Leach JL, Abruzzo T, Jones BV. De novo cerebral arteriovenous malformation: case report and literature review. AJNR Am J Neuroradiol. 2009 Jan;30(1):111-2.
Leach JL, Meyer K, Jones BV, Tomsick TA. Large arachnoid granulations involving the dorsal superior sagittal sinus: findings on MR imaging and MR venography. AJNR Am J Neuroradiol. 2008 Aug;29(7):1335-9. Review.
Yuan W, Holland SK, Jones BV, Crone K, Mangano FT. Characterization of abnormal diffusion properties of supratentorial brain tumors: a preliminary diffusion tensor imaging study. J Neurosurg Pediatr. 2008 Apr;1(4):263-9.
Karunanayaka PR, Holland SK, Yuan W, Altaye M, Jones BV, Michaud LJ, Walz NC, Wade SL. Neural substrate differences in language networks and associated language-related behavioral impairments in children with TBI: a preliminary fMRI investigation. NeuroRehabilitation. 2007;22(5):355-69.
Yuan W, Holland SK, Schmithorst VJ, Walz NC, Cecil KM, Jones BV, Karunanayaka P, Michaud L, Wade SL. Diffusion tensor MR imaging reveals persistent white matter alteration after traumatic brain injury experienced during early childhood. AJNR Am J Neuroradiol. 2007 Nov-Dec;28(10):1919-25.
James L. Leach, MD Neuroradiologist, Department of Radiology and Medical Imaging 513-636-7591 email@example.com
Associate Professor, UC Department of Radiology
Neuroradiology; advanced imaging in epilepsy; multimodal imaging of brain tumors; imaging of stroke; MRI utilization; quality assurance initiatives for neuroradiologic interpretation
James (Jim) Leach, MD, is a neuroradiologist specializing in pediatric neuroradiology at Cincinnati Children's Hospital Medical Center. He grew up in southeastern Ohio and attended Ohio University majoring in zoology with an emphasis on comparative anatomy. He was inducted into the Alpha Omega Alpha honor society as a third-year student.
After seeing a clinical conference given by Bob Lukin, MD, then chief of neuroradiology at the University of Cincinnati College of Medicine, he decided on radiology as a career. He was chief resident of radiology in 1994, and fellow in neuroradiology from 1995-1997 at the University of Cincinnati.
After serving as a staff neuroradiologist at the University of Cincinnati, Dr. Leach spent five years in private practice at Margaret Mary Community Hospital in Batesville, Indiana. Dr. Leach returned to the University of Cincinnati in 2003. He was program director for the Radiology Residency Program from 2003-2006. Dr. Leach began his full time career at Cincinnati Children's in September 2007, focusing on pediatric neuroradiology.
Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, DeGrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with nonlesional epilepsy. Neurology. 2011 Jan 4;76(1):41-8.
Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure. 2010 Dec 9.
Greiner HM, Abruzzo TA, Kabbouche M, Leach JL, Zuccarello M. Rotational vertebral artery occlusion in a child with multiple strokes: a case-based update. Childs Nerv Syst. 2010 Dec;26(12):1669-74.
Guthikonda B, Tobler WD Jr, Froelich SC, Leach JL, Zimmer LA, Theodosopoulos PV, Tew JM Jr, Keller JT. Anatomic study of the prechiasmatic sulcus and its surgical implications. Clin Anat. 2010 Sep;23(6):622-8.
Leung R, Samy RN, Leach JL, Murugappan S, Stredney D, Wiet G. Radiographic anatomy of the infracochlear approach to the petrous apex for computer-assisted surgery. Otol Neurotol. 2010 Apr;31(3):419-23.
Stevenson CB, Leach JL, Gupta A, Crone KR. Cystic degeneration of the cerebellar tonsils in pediatric patients with Chiari Type I malformation. J Neurosurg Pediatr. 2009 Dec;4(6):557-63.
Leach JL, Holland SK. Functional MRI in children: clinical and research applications. Pediatr Radiol. 2010 Jan;40(1):31-49. Review.
Theodosopoulos PV, Leach J, Kerr RG, Zimmer LA, Denny AM, Guthikonda B, Froelich S, Tew JM. Maximizing the extent of tumor resection during transsphenoidal surgery for pituitary macroadenomas: can endoscopy replace intraoperative magnetic resonance imaging? J Neurosurg. 2010 Apr;112(4):736-43.
Morales H, Jones BV, Leach JL, Abruzzo TA. Documented development of a dural arteriovenous fistula in an infant subsequent to sinus thrombosis: case report and review of the literature. Neuroradiology. 2010 Mar;52(3):225-9.
Moore MJ, Vagal AS, Strub WM, Leach JL. Reducing the gray zone: imaging spectrum of hypoperfusion and hypoxic brain injury in adults. Emerg Radiol. 2010 Mar;17(2):123-30.
Francesco T. Mangano, DO, FACS, FACOS Chief, Division of Pediatric Neurosurgery 513-636-4726 firstname.lastname@example.org
Chief, Division of Pediatric Neurosurgery
Director, Pediatric Epilepsy Surgery Program
Associate Professor, UC Department of Neurosurgery
Francesco Mangano joined the Division of Pediatric Neurosurgery at Cincinnati Children's in July 2005, as an associate professor of neurosurgery.A graduate of the Philadelphia College of Osteopathic Medicine, Dr. Mangano completed his neurosurgical residency at Long Island Jewish Medical Center in 2004 followed by a fellowship in pediatric neurosurgery at St. Louis Children's Hospital in St. Louis, Missouri. Since joining the faculty of the division of pediatric neurosurgery at this Cincinnati Children's Hospital Medical Center, he has been instrumental in developing our nationally renowned Pediatric Epilepsy Program and is director of the Pediatric Epilepsy Surgery Program. This program has already given many children a chance to experience a whole new life with marked reduction in the frequency of their debilitating seizures. After extensive evaluation and state of the art imaging and monitoring of the seizures, surgical intervention in many cases can then be exactly targeted to the source of the seizures. An extensive array of surgical techniques may be offered these patients, which ranges from implantation of a vagal nerve stimulator to resection of one whole side of the brain. In addition, he is a co-principal investigator for an NIH-funded multi-institutional research study investigating advanced MRI imaging techniques in children with congenital hydrocephalus. This is only one of his numerous active research projects which have resulted in numerous publications, book chapters and national and international presentations in the fields of epilepsy, diffusion tensor imaging (MRI) of hydrocephalus, traumatic brain injury, and vascular and neoplastic brain lesions. He also has expertise in complex disorders of the spine and spinal cord, including spinal cord tumors, and craniocervical junction.
Dr. Mangano is a member of the American Society of Pediatric Neurosurgeons. He was board certified in 2008 in Neurological Surgery by the American Osteopathic Board of Surgery.
DO: Philadelphia College of Osteopathic Medicine (PCOM), Philadelphia, PA.Residency: NYCOM-Long Island, Jewish Medical Center / North Shore University Health System, New Hyde Park, NY.Fellowship: Washington University School of Medicine-St. Louis Children's Hospital, St. Louis, MO.
Board Certification: Neurological Surgery, American Osteopathic Board of Surgery, 2008.
Kadar AA, Hearst MJ, Collins MH, Mangano FT, Samy RN. Ewing's Sarcoma of the Petrous Temporal Bone: Case Report and Literature Review. Skull Base. 2010 May;20(3):213-7.
Yuan W, Deren KE, McAllister JP 2nd, Holland SK, Lindquist DM, Cancelliere A, Mason M, Shereen A, Hertzler DA, Altaye M, Mangano FT. Diffusion tensor imaging correlates with cytopathology in a rat model of neonatal hydrocephalus. Cerebrospinal Fluid Res. 2010 Nov 5;7:19.
Hertzler DA 2nd, DePowell JJ, Stevenson CB, Mangano FT. Tethered cord syndrome: a review of the literature from embryology to adult presentation. Neurosurg Focus. 2010 Jul;29(1):E1. Review.
Patel NN, Mangano FT, Klimo P Jr. Indirect revascularization techniques for treating moyamoya disease. Neurosurg Clin N Am. 2010 Jul;21(3):553-63. Review.
Air EL, Yuan W, Holland SK, Jones BV, Bierbrauer K, Altaye M, Mangano FT. Longitudinal comparison of pre- and postoperative diffusion tensor imaging parameters in young children with hydrocephalus. J Neurosurg Pediatr. 2010 Apr;5(4):385-91.
Desai R, Stevenson CB, Crawford AH, Durrani AA, Mangano FT. C-1 lateral mass screw fixation in children with atlantoaxial instability: case series and technical report. J Spinal Disord Tech. 2010 Oct;23(7):474-9.
Xiang J, Wang Y, Chen Y, Liu Y, Kotecha R, Huo X, Rose DF, Fujiwara H, Hemasilpin N, Lee K, Mangano FT, Jones B, DeGrauw T. Noninvasive localization of epileptogenic zones with ictal high-frequency neuromagnetic signals. J Neurosurg Pediatr. 2010 Jan;5(1):113-22.
Yuan W, Mangano FT, Air EL, Holland SK, Jones BV, Altaye M, Bierbrauer K. Anisotropic diffusion properties in infants with hydrocephalus: a diffusion tensor imaging study. AJNR Am J Neuroradiol. 2009 Oct;30(9):1792-8.
Xiang J, Liu Y, Wang Y, Kirtman EG, Kotecha R, Chen Y, Huo X, Fujiwara H, Hemasilpin N, Lee K, Mangano FT, Leach J, Jones B, DeGrauw T, Rose D. Frequency and spatial characteristics of high-frequency neuromagnetic signals in childhood epilepsy. Epileptic Disord. 2009 Jun;11(2):113-25.
Charles B. Stevenson, MD Faculty Neurosurgeon, Division of Pediatric Neurosurgery 513-636-4726 email@example.com
Faculty Neurosurgeon, Division of Pediatric Neurosurgery
Assistant Professor, UC Department of Neurosurgery
Brain tumors; spasticity; Chiari malformations; fetal surgery; neurovascular disorders; minimal access surgery
Neuro-oncology; epilepsy; spasticity
Charles Stevenson, MD, rejoined the Division of Pediatric Neurosurgery at Cincinnati Children's Hospital Medical Center in July 2010, after having served for one year as staff neurosurgeon at Kosair Children’s Hospital in Louisville, Kentucky. Prior to completing his fellowship in pediatric neurosurgery at Cincinnati Children’s, he received his neurosurgical training at Vanderbilt University in Nashville, Tennessee. During that time, he also completed a two-year research fellowship in neurosurgical oncology. He graduated from medical school at Vanderbilt University in Nashville, Tennesee. Dr. Stevenson’s interest, specialized training and research background in neuro-oncology make him uniquely qualified to lead our division in its collaborative efforts with the division of neuro-oncology in the Brain and Spinal Tumor program to treat children with primary and recurrent brain tumors. He is assisted in these efforts by leading-edge technology such as the operating room BrainSUITE™, which creates precise three-dimensional maps of the brain and allows for intraoperative MRI imaging to more safely remove particularly complex and deep-seated tumors. Cincinnati Children’s was the first pediatric hospital in the world to offer this technology. In addition, Dr. Stevenson brings expertise in selective dorsal rhizotomy as a treatment for spasticity, which, when added to implantation of baclofen pumps and medical therapy, allows for a wide range of treatment options for patients with spasticity from cerebral palsy or spinal cord injury. He is a member of a multidisciplinary team of specialists that includes neurosurgery, orthopedic surgery, physical medicine and rehabilitation as well as and physical and occupational therapies that offers comprehensive care for children with spasticity.
Dr. Stevenson is a member of the American Society of Pediatric Neurosurgeons. He was board certified in 2013 in neurological surgery by the American Board of Neurological Surgeons.
MD: Vanderbilt University School of Medicine, Nashville, Tennessee, 2001 Residency: Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee Fellowship: Pediatric Neurosurgery, Cincinnati Children's Hospital Medical Center, 2008-09.
Board Certification: Neurological Surgery, American Board of Neurological Surgeons, 2013.
Hertzler II DA, DePowell JJ, Stevenson CB, Mangano FT. Tethered cord syndrome: a review of the literature from embryology to adult presentation. Neurosurgical Focus. 2010;29(1):E1. Stevenson CB, Desai RR, Crawford AH, Durrani AA, Mangano FT. C-1 lateral mass screw fixation in children with atlantoaxial instability: case series and technical report. Journal of Spinal Disorders and Techniques. 2010 Oct;23(7):474-9. Reig AS, Stevenson CB, Tulipan NT. CT-based, fiducial-free frameless stereotaxy for difficult ventriculoperitoneal shunt insertion: experience in 26 consecutive patients. Stereotactic and Functional Neurosurgery. 2010; 88(2):75-80. Stevenson CB, Leach JL, Gupta A, Crone KR. Cystic degeneration of the cerebellar tonsils in pediatric patients with Chiari I malformation. J Neurosurg Ped. 2009; 4(6):557-63. McMillan KM, Ehtesham M, Stevenson CB, Edgeworth ML, Thompson RC, Price RR. T2 detection of tumor invasion within segmented components of glioblastoma multiforme. J Mag Reson Imag. 2009; 29(2):251-7. Ehtesham M, Mapara KY, Stevenson CB, Thompson RC. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Letters. 2009; 274(2):305-12. Ehtesham M, Stevenson CB, Thompson RC. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery. 2008; 63(4):E820. Stevenson CB, Ehtesham M, McMillan KM, Valadez JG, Edgeworth ML, Price RR, Abel TW, Mapara KY, Thompson RC. CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peri-tumoral T2-weighted MRI signal abnormalities. Neurosurgery. 2008;63(3):560-9. Johnson MD, Stevenson CB, Thompson RC, Atkinson J, Boyer P. 31-year-old woman with hemiparesis . Brain Pathology. 2007;17(2):255-7.
Stevenson CB, Crone KR. Head injury. In Operative Pediatric Surgery Ziegler MM, Azizkhan RG, Weber T, von Allmen D (eds.). 2nd Edition. Mcgraw-Hill: New York ,NY, 2012.
David W. Pruitt, MD Medical Director, Inpatient Pediatric Rehabilitation Unit 513-636-7480 firstname.lastname@example.org
Medical Director, Inpatient Pediatric Rehabilitation Unit
Director, Pediatric Rehabilitation Medicine Fellowship
Associate Professor, UC Department of Pediatrics
UC Department of Neurology and Rehabilitation Medicine
Inpatient pediatric rehabilitation; pediatric cancer rehabilitation; pediatric neuro-oncology
BS: University of Notre Dame, Notre Dame, IN, 1994.
MD: Loyola University Stritch School of Medicine, Chicago, IL, 1998.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center; Physical Medicine and Rehabilitation, University of Cincinnati, Cincinnati, OH.
Certification: Physical Medicine and Rehabilitation, recertification 2014; Pediatric Rehabilitation Medicine, recertification 2014.
Visscher M, King A, Nie AM, Schaffer P, Taylor T, Pruitt D et al. A quality improvement collaborative project to reduce pressure ulcers in PICUs. Pediatrics. 2013: 131(6): e1950-60.
Pruitt DW, Ayyangar R, Craig K, White A, Neufeld JA. Pediatric brain tumor rehabilitation. J Pediatr Rehabil Med. 2011; 4(1): 59-70.
Pruitt DW, Tsai T. Common Comorbidities Associated With Cerebral Palsy. In: LJ Michaud (ed.): Physical Medicine and Rehabilitation Clinics of North America, 2009; 20(3):453-67.
Susan R. Rose, MD 513-636-4744 email@example.com
Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer
Susan Rose is professor in the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.
She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi Anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.
MD: Case Western Reserve School of Medicine, 1980.
MEd: School Psychology, University of Dayton, 1972.
Residency: The Cleveland Clinic, 1983.
Fellowship: National Institutes of Health, 1986.
Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.
Auble BA, Makoroff K, Bollepalli S, Weis T, Colliers T, Khoury J, Rose SR. Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. J Neurotrauma. 2014 Feb 15;31(4):321-6.
Myers KC, Rose SR, Rutter MM, Mehta PA, Cole T, Harris RE. Endocrine evaluation of children with and without Shwachman-Bodian-Diamond syndrome gene mutations and Shwachman-Diamond syndrome. J Pediatr. 2013 Jun;162(6):1235-40.
Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec;22(12):1046-56.
Rose SR, Myers K, Rutter MM, Mueller R, Khuory JC, Mehta PA, Harris RE, Davies SM. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012 Oct;59(4):690-6.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011 Dec 20;29(36):4776-80.
Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L, Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr. 2010 Dec;157(6): 894-9.
Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010 Oct;157(4):662-7.
Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn screening rates. Pediatrics. 2010 Nov;126(5):910-6.
Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Courtney CH, Gonc EN, Maghnie M, Oelkers W, Rose SR, Soule SG, Tordjman K, Consortium for evaluation of corticotropin test in hypothalamic-pituitary insufficiency. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53.
Rose SR. Pharmacologic and physiologic regulators of the nocturnal TSH surge; A clinical research center study. Recent Advances and Research Updates. ISSN 0972-4699, 2007; 8:219-29.
Meilan M. Rutter, MD, FRACP 513-636-4744 firstname.lastname@example.org
Bone health and calcium metabolism; disorders of growth, puberty and sex development; endocrine function in cancer survivors; endocrine function in neuromuscular disorders
Insulin-like growth factor-1 (IGF-1) therapy in Duchenne Muscular Dystrophy
Meilan Rutter is board-certified in Pediatrics and Pediatric Endocrinology. She is an Assistant Professor of Pediatrics in the Division of Endocrinology, and joined the faculty of Cincinnati Children's Hospital Medical Center in 2008. Currently, Dr. Rutter is assistant director of the Pediatric Endocrinology Fellowship Program.
Dr. Rutter received her degrees of Bachelor of Medicine and Bachelor of Surgery (MB, BCh) from the University of Wales College of Medicine. She completed her training in Pediatrics in New Zealand, and was admitted to Fellowship of the Royal Australasian College of Physicians (FRACP) in 1995. She underwent fellowship training in Pediatric Endocrinology at Cincinnati Children's. She completed further pediatric residency training to achieve American Board of Pediatrics specialty and subspecialty board certification.
Dr. Rutter treats children and adolescents with endocrine disorders and diabetes mellitus. She serves as a consultant for the Neuromuscular Comprehensive Care Center and the Neuro-Oncology program at Cincinnati Children's. Additionally. she is a member of the Disorders of Sex Development interdisciplinary team.
MB, BCh: University of Wales College of Medicine, Cardiff, United Kingdom.FRACP: Royal Australasian College of Physicians, New Zealand.Residency: Auckland Children's Hospital and Dunedin Hospital, New Zealand; Cincinnati Children's, Cincinnati, OH.
Fellowship: Pediatric Endocrinology, Cincinnati Children's, Cincinnati, OH.
Certification: General Pediatrics, American Board of Pediatrics, 2002; Pediatric Endocrinology, American Board of Pediatrics, 2003; Pediatrics, Fellowship of the Royal Australasian College of Physicians, 1995.
Rose SR, Rutter MM, Mueller R, Harris M, Hamon B, Fletcher Bulluck A, Smith FO. Bone mineral density is normal in children with Fanconi anemia. Pediatr Blood Cancer. 2011 Dec 1;57(6):1034-8.
Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne Muscular Dystrophy. Neuromuscul Disord. 2011 Apr;21(4):298-303.
Wong BL, Rutter MM, Rose SR, Clark E, Vonderhaar K. Growth hormone therapy in Duchenne Muscular Dystrophy. Best Evidence Statement, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. 2009.
Rutter MM. What is an endocrinologist and why is endocrine care important for Duchenne? Action Duchenne newsletter. 2009.
Murray R, Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 90th Annual Meeting. Highlights. 2008;16(4):1-36.
Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 89th Annual Meeting. Highlights. 2007;15(3):2-30.
Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr. 2007 Aug;19(4):480-7.
Rutter MM, Markoff E, Clayton L, Akeno N, Zhao G, Clemens TL, Chernausek SD. Osteoblast-specific expression of insulin-like growth factor-1 in bone of transgenic mice induces insulin-like growth factor binding protein-5. Bone. 2005 Feb;36(2):224-31.
Rutter MM, Prahalad S, Passo M, Backeljauw PF. Idiopathic hypercalcemia and eosinophilic fasciitis: a novel association. J Pediatr Endocrinol Metab. 2004 Sep;17(9):1251-4.
Rutter MM, Smith EP. Pseudohypoparathyroidism type Ia: late presentation with intact mental development. J Bone Miner Res. 1998 Jul;13(7):1208-9.
Bruce J. Aronow, PhD Co-director, Computational Medicine Center 513-636-0263 email@example.com
Co-director, Computational Medicine Center
Dr. Aronow's research is devoted to unraveling both the role and mechanism by which the functional capabilities of the human genome shape human health and our ability to adapt to stressful challenges. His lab is using a variety of available structural and functional genomic and biological systems descriptive data to form models of how biological systems assemble, adapt and become impaired in disease. The lab's overall hypothesis is that by interconnecting as much experimental and observational information as possible, we can gain new insights into the mechanisms by which different biological systems can achieve health or healthy adaptation, or undergo disease processes. More specific, with the co-leadership of Anil Jegga, DVM, the lab is identifying genetic features that control gene expression including cis-elements, trans factors and microRNAs, which normally work together in extended cell, tissue, organ and systems networks to enable development and homeostasis. Alterations of these features can alter phenotypes and increase or decrease disease. Some of the lab's work includes the identification of conserved, diverged and evolved cis-element clusters that are acted on by transcription and chromatin proteins. The lab has developed a Web-based tool called GenomeTraFaC that at present allows discovery of shared cis-elements in conserved non-coding sequences of mice and humans.
Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis and rheumatism. 2009 Jul;60(7):2102-12.
Qu XA, Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics. 2009 May;10 Suppl 5:S4.
Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature. 2009 Apr 23;458(7241):1039-42.
Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res. 2009 Apr 1;69(7):2902-11.
Chen J, Aronow BJ, Jegga AG. Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics. 2009 Feb;10:73.
Shen H, Powers N, Saini N, Comstock CE, Sharma A, Weaver K, et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 2008 Dec 15;68(24):10154-62.
Brunskill EW, Aronow BJ, Georgas K, Rumballe B, Valerius MT, Aronow J, et al. Atlas of gene expression in the developing kidney at microanatomic resolution. Developmental cell. 2008 Nov;15(5):781-91.
Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, et al. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. Cancer Gene Ther. 2008 Nov;15(11):733-41.
Kucherlapati MH, Yang K, Fan K, Kuraguchi M, Sonkin D, Rosulek A, et al. Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15493-8.
Gudivada RC, Qu XA, Chen J, Jegga AG, Neumann EK, Aronow BJ. Identifying disease-causal genes using Semantic Web-based representation of integrated genomic and phenomic knowledge. J Biomed Inform. 2008 Oct;41(5):717-29.
Kenneth J. Campbell, PhD 513-636-0246 firstname.lastname@example.org
Molecular genetic control of mammalian forebrain development
MS: University of Toronto, Toronto, Canada, 1990.
PhD: University of Lund, Lund, Sweden, 1994.
Postdoctoral Fellow: Skirball Institute, NYU Med Center, 1995-97.
Biplab Dasgupta, PhD, MS Member, Cancer Biology and Neural Tumors Program 513-803-1370 email@example.com
Biplab Dasgupta, PhD, MS, completed his doctorate in molecular biology and immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an assistant professor of pediatrics. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.
Xiaona Liu, Rishi Raj Chhipa and Biplab Dasgupta*. The Selective AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Mol Cancer Ther. *Corresponding author. 2014 Mar:13(3):596-605
Xiaona Liu, Rishi Raj Chhipa, Shabnam Pooya, Matthew Wortman, Sara Yachishin, Ashish Kumar, Lionel Chow, Xuan Zhou, Ying Sun, Brian Quinn, Christopher McPherson, Ronald Warnick, Adi Kendler, Sailendra Giri, Jeroen Poels, Koennard Nogra, Benoit Viollet, Gregory A. Grabowski and Biplab Dasgupta*. Novel mechanisms of mTOR and cdc25c regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sc U S A. *Corresponding author. 2014 Jan 28;111(4):E435-44.
Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B*. Direct inhibition of Retinoblastoma phosphorylation by Nimbolide causes cell cycle arrest and suppresses glioblastoma growth. Clin Cancer Research. 2014 Jan 1:20(1):199-212.
Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, Milbrandt J. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012; 32: 2837-48. Cover article. *Corresponding author.
Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70.
Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22.
Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57.
Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94.
Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.
Rachid Drissi, PhD 513-636-4266 firstname.lastname@example.org
Masato Nakafuku, MD, PhD Ohio Eminent Scholar 513-636-9389 email@example.com
Ohio Eminent Scholar
Development and regeneration of the central nervous system (CNS); therapeutic strategies for neurological diseases
Visit the Nakafuku Lab.
Pei Z, Wang B, Chen G, Nagao M, Nakafuku M, Campbell K. Homeobox genes Gsx1 and Gsx2 differentially regulate telencephalic progenitor maturation. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1675-80.
Shereen A, Nemkul N, Yang D, Adhami F, Dunn RS, Hazen ML, Nakafuku M, Ning G, Lindquist DM, Kuan CY. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cereb Blood Flow Metab. 2010 Dec 8.
Nagao M, Campbell K, Burns K, Kuan CY, Trumpp A, Nakafuku M. Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway. J Cell Biol. 2008 Dec 29;183(7):1243-57.
Sugimori M, Nagao M, Parras CM, Nakatani H, Lebel M, Guillemot F, Nakafuku M. Ascl1 is required for oligodendrocyte development in the spinal cord. Development. 2008 Apr;135(7):1271-81.
Nakafuku M, Nagao M, Grande A, Cancelliere A. Revisiting neural stem cell identity. Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):829-30.
Kim HJ, Sugimori M, Nakafuku M, Svendsen CN. Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Exp Neurol. 2007 203:394-405.
Nagao M, Sugimori M, Nakafuku M. Cross talk between notch and growth factor/cytokine signaling pathways in neural stem cells. Mol Cell Biol. 2007 Jun;27(11):3982-94.
Parras CM, Hunt C, Sugimori M, Nakafuku M, Rowitch D, Guillemot F. The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes. J Neurosci. 2007 27:4233-4242.
Sugimori M, Nagao M, Bertrand N, Parras CM, Guillemot F, Nakafuku M. Combinatorial actions of patterning and HLH transcription factors in the spatiotemporal control of neurogenesis and gliogenesis in the developing spinal cord. Development. 2007 Apr;134(8):1617-29.
Ohori Y, Yamamoto S, Nagao M, Sugimori M, Yamamoto N, Nakamura K, Nakafuku M. Growth factor treatment and genetic manipulation stimulate neurogenesis and oligodendrogenesis by endogenous neural progenitors in the injured adult spinal cord. J Neurosci. 2006 Nov 15;26(46):11948-60.
Dao Pan, PhD 513-636-6315 Dao.Pan@cchmc.org
Hematopoietic stem cells; Mesenchymal stem/progenitor cells; Gene therapy; Human genetics; Translational research; Lysosomal storage diseases
Visit the Pan Lab.
Wang D, El-Amouri SS, Dai M, Kuan A, Hui D, Brady RO and Pan D. Engineering a lysosomal enzyme with receptor-binding domain of ApoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci USA, 110:2999-3004, 2013.
El-Amouri SS, Cao P, Miao CH and Pan D. Secreted luciferase for in vivo evaluation of systemic protein delivery in mice, Mol Biotech, 53:63-73, 2013.
Pan D*, Kalfa TA, Wang D, Risinger M, Crable S, Ottlinger A, Mount DB, Hubner CA, Franco RS, and Joiner CH*. KCl cotransporter gene expression during human and murine erythroid differentiation, J Biol Chem, 286(35): 30492-30503, 2011. co-correspondent authors.
Pan D. Cell- and Gene-Based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses. Curr Pharm Biotechnol. 2011 Jan 11.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Pan D. In situ (in vivo) gene transfer into murine bone marrow stem cells. Methods Mol Biol. 2009;506:159-69.
Wang D, Worsham DN, Pan D. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction. J Gene Med. 2008 Mar;10(3):249-59.
Pan D, Sciascia A 2nd, Vorhees CV, Williams MT. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res. 2008 Jan 10;1188:241-53.
Worsham DN, Schuesler T, von Kalle C, Pan D. In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther. 2006 Oct;14(4):514-24.
Nancy Ratner, PhD Beatrice C. Lampkin Chair, Cancer Biology 513-636-9469 firstname.lastname@example.org
Beatrice C. Lampkin Chair, Cancer Biology
Program Leader, Cancer and Biology and Neural Tumors Program
Preclinical testing in Neurofibromatosis Tumors
Genetic mutations in tumor suppressor genes; development of the nervous system; peripheral nerve tumor formation
Visit the Ratner Lab.
Nancy Ratner, PhD, is interested in understanding mechanisms of peripheral nerve tumor (neurofibroma) formation in Neurofibromatosis type 1 (NF1), a common inherited disorder in which children are predisposed to cancer of the nervous system, to learning problems, bone disorders, and other cancers. She identified EGFR and MEK as potential therapeutic targets in NF1 peripheral nerve tumorigenesis, and has developed cell culture and mouse models of NF1 nerve tumorigenesis. Her laboratory has also used analysis of gene expression to identify critical genes in neurofibroma and their malignant derivatives, MPNST.
Dr. Ratner received her bachelor's from Brown University, her doctorate from Indiana University, and was a postdoctoral fellow at Washington University in St. Louis. She was a member of the faculty at the University of Cincinnati from 1987 to 2004. Dr. Ratner is currently a professor in the Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, and the program leader for Cancer Biology and Neural Tumors Program in the Cancer and Blood Diseases Institute where she holds the Beatrice C. Lampkin Endowed chair in cancer biology and serves as PI of the NINDS P50 “Cincinnati Center in NF Research.”
Dr. Ratner is an active member of the International Consortium on the Molecular Biology of NF1, NF2, and schwannomatosis and was a member of the advisory board for the National Neurofibromatosis Foundation (now Children’s Tumor Foundation) from 1989 to 2007. She chaired the Department of Defense Neurofibromatosis Research Program Integration Panel in 2008, and currently serves as a member of the James McDonnell Brain Tumor Research Advisory Board. She received the von Recklinghausen Award from the Children’s Tumor Foundation in 2010 and the Jacob K. Javits Neuroscience Investigator Award (NIH-NINDS MERIT Award) in 2014.
PhD: Indiana University, 1982.
BA: Brown University, 1975.
Fellowship: Washington University St. Louis, 1982-1987.
Mayes DA, Rizvi TA, Titus-Mitchell HA, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Stemmer-Rachamimov AO, Ratner N. Nf1 loss and Ras activation in Oligodendrocytes induce NOS-driven Defects in Myelin and Vasculature. Cell Reports. 2013 Sep 26;4(6):1197-212.
Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity B, Beckmann DA, Wolf N, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra S, Ratner N, Largaespada DA. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies novel genes and genetic pathways driving tumorigenesis. Nature Genetics. 2013;45(7):756-66.
Watson AL, Rahrmann EP, Moriarity B, Choi K, Conboy C, Greeley A, Halfond A, Anderson L, Wahl B, Keng VW, Rizzardi A, Forser C, Collins MH, Sarver A, Wallace M, Schmechel S, Ratner N, Largaespada DA. Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance. Cancer Discov. 2013 Jun;3(6):674-689.
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, West BL, Bollag G, Ratner N. Neurofibroma associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neurpathol. 2013;125(1):159-68.
Jessen WJ, Miller SJ, Jousma E, Rizvi TA, Eaves D, Wu J, Widemann B, Kim M-O, Dombi E, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK Inhibition Exhibits Efficacy in Human and Mouse Neurofibromatosis Tumors Despite Transcriptional Feedback onto ERK. J Clin. Invest. 2013 Jan 2;123(1):340-7.
Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N. Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target. Clin Canc Res. 2012 Sep 15;18(18):5020-30.
Hennigan RF, Moon CO, Parysek LM, Monk KR, Morfini G, Berth S, Brady ST, Ratner N. Merlin Modulates Microtubule-Based Vesicle Trafficking via Rac, MLK and p38SAPK. Oncogene. 2012;29(3):368-79.
Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N. Perinatal or Adult Nf1 Inactivation Using Tamoxifen-Inducible PlpCre Each Cause Neurofibroma Formation. Cancer Res. 2011 Jul 1;71(13):4675-85.
Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page G, Worley P, Aronow BJ, Schorry E, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010;16 5048-57.
Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga A, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N. Integrative genomic analyses of neurofibromatosis tumors identify SOX9 as biomarker and survival gene. EMBO Mol Medicine. 2009 1(4): 236-48.
Mitogenic Activities in Neurofibromatosis. Principle Investigator. Sept 2011-2016. NIH-R01 NS 28840-20.
Preclinical Testing: GEM-Neurofibroma. Principal Investigator. Children's Tumor Foundation. Aug 2013 - Jul 2016.
Cellular and Molecular Contributors to Neurofibroma Formation. Principal Investigator. U.S. Army NF Program. Jul 2012 - Jun 2015. DOD W81XWH-11-1-0057
Identification of Neurofibroma Growth and Drug Resistance Pathways. Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Apr 2014 - Mar 2016.
Ras Proteins in Nerve Tumorigenesis. Principal Investigator. Apr 2014 - Mar 2019. 1R01 NS083580-01A1.
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors. Co-Principal Investigator. Jul 2014 - Jun 2016. 1R21NS084885-01A1.
Disordered Wnt/b-catenin signaling in MPNST Development and Maintenance. Co-Principal Investigator. Oct 2014 - Sep 2019. 1R01NS086219-01A1.
Can targeted therapy prevent neurofibroma growth in mice? Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Sep 2014 - Aug 2016.
Jianqiang Wu, MD, MS Member, Cancer Biology and Neural Tumors Program 513-636-0955 email@example.com
Wu J, Patmore DM, Jousma E, Eaves DW, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene. 2013.
Jessen W, Miller S, Jousma E, Wu J, Rizvi T, Eaves D, Widemann B, Dombi E, Dudley A, Niwa-Kawakita M, et al. MEK Inhibition Exhibits Efficacy in Human and Mouse Neurofibromatosis Tumors . J. Clin Invest. 2013;123(1):340-7.
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, and Ratner N. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013;125(1):159-68.
Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner N. In vivo regulation of TGFβ by R-Ras2 revealed through loss of the RasGAP protein Nf1.Cancer Res. 2012;72(20):5317-27.
Wu J, Dombi E, Jousma E, Dunn SR, Lindquist D, Schnell BM, Kim M , Kim A, Cripe TP, Ratner N. Preclinical testing of Sorafenib and RAD001 in the Nf1 fl/fl;DhhCre mouse model of plexiform Neurofibroma using magnetic resonance imaging. Pediatric Blood & Cancer. 2012;58(2):173-80.
Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, Patmore DM, Hegde RS, Cripe TP, Cancelas JA, Collins MH, Ratner N. Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene. 2010;29(3):368-79.
Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog expressing cells. Cancer Cell. 2008;13(2):105-116.
*Williams JP, *Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor population that confers tumorigenic potential. Cell Stem Cell. 2008; 3(6):658-69 (*contributed equally to the work).
Monk KR, Wu J, Williams JP, Finney BA, Fitzgerald ME, Filippi MD, Ratner N. Mast cells can contribute to axon-glial dissociation and fibrosis in peripheral nerve. Neuron Glia Biology. 2007;3:233-244.
Wu J, Crimmins JT, Monk KR, Williams JP, Fitzgerald ME, Tedesco S, Ratner N. Perinatal Epidermal Growth Factor Receptor Blockade prevents Peripheral Nerve Disruption in a Mouse Model Reminiscent of Benign World Health Organization Grade I Neurofibroma. Am J Pathol. 2006; 168(5):1686-96.
*Ling BC, *Wu J, Miller SJ, Monk KR, Shamekh R, Rizvi TA, Decourten-Myers G, Vogel KS, DeClue JE, Ratner N. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell. 2005;7(1):65-75. Cover, (*contributed equally to the work).
Yutaka Yoshida, PhD 513-803-0943 firstname.lastname@example.org
Molecular mechanisms of neural circuit formation in the developing spinal cord.
Visit the Yoshida Lab.
BS: Keio University, 1994.
PhD: University of Tokyo, 1999.
Postdoctoral fellow: University of Tokyo, 1999-2002; Columbia University, 2002-2007.
Fukuhara K, Imai F, Ladle DR, Katayama K, Leslie JR, Arber S, Jessell TM, Yoshida Y. Specificity of monosynaptic sensory connections imposed by repellent sema3e-plexinD1 signaling. Cell Rep. 2013 Nov 14;5(3):748-58.
Katayama K, Imai F, Campbell K, Lang RA, Zhneg Y, Yoshida Y. RhoA and Cdc42 are required in pre-migratory progenitors of the medial ganglionic eminence ventricular zone for proper cortical interneuron migration. Development. 2013 Aug;140(15):3139-45.
Katayama K, Leslie JR, Lang RA, Zheng Y, Yoshida Y. Left-right locomotor circuitry depends upon RhoA-driven organization of the neuroepithelium in the developing spinal cord. Journal of Neuroscience. 2012 Jul 25;32(30):10396-407.
Leslie JR, Imai F, Fukuhara K, Takegahara N, Rizvi TA, Friedel RH, Wang F, Kumanogoh A, Yoshida Y. Ectopic myelinating oligodendrocytes in the dorsal spinal cord as a consequence of changing semaphorin6D signaling inhibit synapse formation. Development. 2011. Katayama K, Melendez J, Baumann JM, Leslie JR, Chauhan BK, Nemkul N, Lang RA, Kuan CY, Zheng Y, Yoshida Y. Loss of RhoA in neural progenitor cells causes the disruption of adherens junctions and hyperproliferation. Proc Natl Acad Sci U S A. May 3;108(18):7607-12. 2011.
Pecho-Vrieseling E, Sigrist M, Yoshida Y, Jessell TM, and Arber S. Specificity of Monosynaptic Sensory-Motor Connections Encoded by Sema3e-PlexinD1. Nature. 459:842-6. 2009.Yoshida Y, Han B, Mendelsohn M, Jessell TM. PlexinA1 signaling directs the segregation of proprioceptive sensory axons in the developing spinal cord. Neuron. 52:775-88. 2006.Gu C*, Yoshida Y*, Livet J., Reimert DV, Mann F, Merte J, Henderson CE, Jessell TM, Kolodkin AL, Ginty DD. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science. 307:265-8. 2005. (* denotes equal contribution)
Yoshida Y, Nakamura T, Komoda M, Satoh H, Suzuki T, Tsuzuku JK, Miyasaka T, Yoshida EH, Umemori H, Kunisaki RK, Tani K, Ishii S, Mori S, Suganuma M, Noda T, Yamamoto T. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev. 17:1201-6. 2003.Yoshida Y, Tanakam S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, Miyazono K, Noda M, Noda T, Yamamoto T. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell. 103:1085-97. 2000.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center